Gardasil was 13% of Merck’s sales in 2024, and roughly half of Gardasil sales tie to China. This increases reliance on Merck’s oncology drug Keytruda (46% of sales), which could face ...

Gardasil was 13% of Merck's sales in 2024, and roughly half of Gardasil sales tie to China. This increases reliance on Merck's oncology drug Keytruda (46% of sales), which could face biosimilar ...

Around 13 million Americans become infected with the potentially cancer-causing human papillomavirus (HPV) each year. Fortunately, the HPV vaccine can help protect you and your family. Dr. Judith ...

They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.

Getting the HPV vaccine in early adolescence may lower the risk of HPV-related cancers before exposure occurs. Learn about starting and cutoff ages here.

Gardasil vaccine protects against cancer-causing ... Analysts had been projecting earnings of $9.13 per share on $67.07 billion in sales, according to FactSet. For the recently completed fourth ...

The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...

Gardasil sales have slumped there for a few quarters ... The data firm FactSet says analysts had been projecting earnings of $9.13 per share on $67.07 billion in sales for the Rahway, New Jersey ...

Both forecasts came in below the average analyst expectation for revenue of $67.07 billion, and adjusted earnings per share of $9.13.